Promising Nanotechnology Stocks To Consider - August 4th

Key Points

• MarketBeat highlights seven promising nanotechnology stocks including Onto Innovation, OSI Systems, and NVE, which have shown high trading volumes recently.
• Onto Innovation's shares recently traded at $96.89, while OSI Systems reached $221.58, both showing upward movement during trading.
• Biodexa Pharmaceuticals is developing treatments for Type 1 diabetes and certain brain cancers, with its lead product currently in Phase II studies.

Onto Innovation, OSI Systems, NVE, Nano Dimension, Biodexa Pharmaceuticals, Clene, and Clene are the seven Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are shares of publicly traded companies that research, develop and commercialize materials, devices or systems engineered at the nanoscale (one billionth of a meter). These firms apply nanoscience across industries like electronics, medicine, energy and materials science to exploit unique properties that emerge at extremely small dimensions. Investing in nanotechnology stocks provides exposure to cutting-edge innovation but can carry higher volatility and risk due to the nascent and rapidly evolving nature of the field. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

Onto Innovation (ONTO)

Onto Innovation Inc. engages in the design, development, manufacture, and support of process control tools that performs optical metrology. The company offers lithography systems and process control analytical software. It also offers process and yield management solutions, and device packaging and test facilities through standalone systems for optical metrology, macro-defect inspection, packaging lithography, and transparent and opaque thin film measurements.

Shares of ONTO stock traded up $2.59 during mid-day trading on Monday, hitting $96.89. The stock had a trading volume of 616,088 shares, compared to its average volume of 1,216,914. Onto Innovation has a 12-month low of $85.88 and a 12-month high of $228.42. The firm has a market capitalization of $4.73 billion, a P/E ratio of 21.94, a price-to-earnings-growth ratio of 0.61 and a beta of 1.44. The firm's 50-day moving average is $98.12 and its two-hundred day moving average is $126.71.

Read Our Latest Research Report on ONTO

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

NASDAQ:OSIS traded up $2.01 during mid-day trading on Monday, hitting $221.58. 58,420 shares of the company's stock traded hands, compared to its average volume of 223,744. The company has a fifty day moving average of $222.49 and a 200 day moving average of $207.98. OSI Systems has a twelve month low of $129.18 and a twelve month high of $241.64. The company has a market capitalization of $3.72 billion, a P/E ratio of 26.96, a P/E/G ratio of 1.86 and a beta of 1.31. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.38 and a current ratio of 2.11.

Read Our Latest Research Report on OSIS

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

NVE stock traded up $0.28 during trading hours on Monday, hitting $60.07. 41,536 shares of the stock traded hands, compared to its average volume of 43,733. NVE has a 1 year low of $51.50 and a 1 year high of $88.50. The stock has a market capitalization of $290.56 million, a price-to-earnings ratio of 20.02 and a beta of 1.19. The firm's 50 day moving average price is $72.60 and its 200-day moving average price is $68.67.

Read Our Latest Research Report on NVEC

Nano Dimension (NNDM)

Nano Dimension Ltd., together with its subsidiaries, engages in additive manufacturing solutions in Israel and internationally. The company offers 3D printers, comprising AME systems, which are inkjet printers, that produces Hi-PEDs by depositing proprietary conductive and dielectric substances, as well as integrates in-situ capacitors, antennas, coils, transformers, and electromechanical components; micro additive manufacturing systems, a digital light processing printers (DLP) that achieves production-grade polymer and composite parts; and industrial additive manufacturing systems, that utilizes a patented foil system that fabricates ceramic and metal parts.

Shares of Nano Dimension stock traded up $0.05 during mid-day trading on Monday, reaching $1.40. 1,016,652 shares of the stock traded hands, compared to its average volume of 2,089,592. The business has a 50-day moving average of $1.51 and a 200 day moving average of $1.79. Nano Dimension has a fifty-two week low of $1.34 and a fifty-two week high of $2.74. The stock has a market capitalization of $303.11 million, a PE ratio of -3.49 and a beta of 1.13.

Read Our Latest Research Report on NNDM

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Shares of NASDAQ:BDRX traded up $0.19 during midday trading on Monday, hitting $6.89. The company had a trading volume of 29,485 shares, compared to its average volume of 193,343. Biodexa Pharmaceuticals has a twelve month low of $5.85 and a twelve month high of $166.93. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.75 and a quick ratio of 1.75. The business's 50-day simple moving average is $9.55 and its 200-day simple moving average is $19.69.

Read Our Latest Research Report on BDRX

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

CLNN stock traded up $0.19 during midday trading on Monday, hitting $3.68. 49,319 shares of the company's stock were exchanged, compared to its average volume of 73,177. The business has a 50-day simple moving average of $3.82 and a two-hundred day simple moving average of $3.75. The stock has a market capitalization of $30.39 million, a PE ratio of -0.91 and a beta of 0.55. Clene has a 1-year low of $2.28 and a 1-year high of $6.96.

Read Our Latest Research Report on CLNN

Clene (CLNNW)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Shares of NASDAQ:CLNNW traded down $0.00 on Monday, hitting $0.04. 1,659 shares of the company's stock were exchanged, compared to its average volume of 10,603. Clene has a 1-year low of $0.02 and a 1-year high of $0.08. The firm's 50-day moving average is $0.03 and its 200 day moving average is $0.03.

Read Our Latest Research Report on CLNNW

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.